ADDERALL XR(R) - Litigation Update

Impax Laboratories, Inc. (OTC:IPXL) and Shire plc(LSE:SHP)(NASDAQ:SHPGY)(TSX:SHQ) announce that, as published today onthe Court's electronic docket, the U.S. District Court of the Districtof Delaware has granted the parties' request to extend until January26, 2006 the deadline for the parties to submit the pre-trial order.The Court also agreed to stay the matters of the case pendingsettlement negotiations. The case is listed on the docket as ShireLaboratories Inc. v. Impax Laboratories, Inc. and is a patentinfringement lawsuit involving Shire's U.S. patents Nos. 6,322,819 and6,605,300, in connection with Impax's attempt to market a genericversion of Shire's ADDERALL XR prior to the expiration of thosepatents.

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialtypharmaceutical company applying its formulation expertise and drugdelivery technology to the development of controlled-release andspecialty generics in addition to the development of branded products.IMPAX markets its generic products through its Global Pharmaceuticalsdivision and intends to market its branded products through the IMPAXPharmaceuticals division. Additionally, where strategicallyappropriate, IMPAX has developed marketing partnerships to fullyleverage its technology platform. IMPAX Laboratories is headquarteredin Hayward, California, and has a full range of capabilities in itsHayward and Philadelphia facilities. For more information, pleasevisit the Company's Web site at: www.impaxlabs.com.

About Shire PLC

Shire's strategic goal is to become the leading specialtypharmaceutical company that focuses on meeting the needs of thespecialist physician. Shire focuses its business on central nervoussystem (CNS), gastrointestinal (GI), general products (GP) and humangenetic therapies (HGT) - all being areas in which Shire has acommercial presence. The structure is sufficiently flexible to allowShire to target new therapeutic areas to the extent opportunitiesarise through acquisitions. Shire believes that a carefully selectedportfolio of products with a strategically aligned and relativelysmall-scale sales force will deliver strong results. Shire's focusedstrategy is to develop and market products for specialty physicians.This approach aims to deliver increased returns and lower risks.Shire's in-licensing and merger and acquisition efforts are focused onproducts in niche markets with strong intellectual property protectioneither in the US or Europe.

For further information on Shire, please visit the Company'swebsite: www.shire.com

"Safe Harbor" statement under the Private Securities LitigationReform Act of 1995:

To the extent any statements made in this news release containinformation that is not historical, these statements areforward-looking in nature and express the beliefs and expectations ofmanagement. Such statements are based on current expectations andinvolve a number of known and unknown risks and uncertainties thatcould cause IMPAX's future results, performance or achievements todiffer significantly from the results, performance or achievementsexpressed or implied by such forward-looking statements. Such risksand uncertainties include, but are not limited to, possible adverseeffects resulting from the delisting of IMPAX's stock, IMPAX's delayin filing its 2004 Form 10-K and its Form 10-Q's for the first threequarters of 2005, IMPAX's ability to obtain sufficient capital to fundits operations, the difficulty of predicting FDA filings andapprovals, consumer acceptance and demand for new pharmaceuticalproducts, the impact of competitive products and pricing, IMPAX'sability to successfully develop and commercialize pharmaceuticalproducts, IMPAX's reliance on key strategic alliances, the uncertaintyof patent litigation, the availability of raw materials, theregulatory environment, dependence on patent and other protection forinnovative products, exposure to product liability claims,fluctuations in operating results and other risks detailed from timeto time in IMPAX's filings with the Securities and ExchangeCommission. Forward-looking statements speak only as to the date onwhich they are made, and IMPAX undertakes no obligation to updatepublicly or revise any forward-looking statement, regardless ofwhether new information becomes available, future developments occuror otherwise.